RECRUITING

A Study of MET233 in Individuals With Obesity or Overweight

Description

The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-weekly subcutaneous injections of MET233 in otherwise healthy adults with overweight or obesity. The trial will be conducted in three parts. Part A consists of single ascending dose (SAD) cohorts of MET233 or placebo. Part B consists of multiple ascending dose (MAD) cohorts, with participants treated with five once-weekly doses of MET233 or placebo. In Part C, participants will receive once-weekly doses of MET233 or placebo for 12 weeks, followed by a single higher, potential monthly dose.

Conditions

Obesity and Overweight
Talk to us

Related Conditions:

Obesity and Overweight

Study Overview

On this page

Study Details

Study overview

The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-weekly subcutaneous injections of MET233 in otherwise healthy adults with overweight or obesity. The trial will be conducted in three parts. Part A consists of single ascending dose (SAD) cohorts of MET233 or placebo. Part B consists of multiple ascending dose (MAD) cohorts, with participants treated with five once-weekly doses of MET233 or placebo. In Part C, participants will receive once-weekly doses of MET233 or placebo for 12 weeks, followed by a single higher, potential monthly dose.

A Randomized, Double-blind, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MET233 in Otherwise Healthy Adult Participants With Obesity or Overweight

A Study of MET233 in Individuals With Obesity or Overweight

Condition
Obesity and Overweight
Intervention / Treatment

-

Contacts and Locations

Cypress

MET233 Research Site 001, Cypress, California, United States, 90630

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adult (≥18 to ≤70 years) male and female participants with obesity or overweight (BMI 27.0 kg/m2 to 38.0 kg/m2, inclusive) but otherwise healthy.
  • * Female who is lactating or who is pregnant according to the pregnancy test at the Screening visit or prior to the first study drug administration
  • * Seated blood pressure higher than 160/95 mmHg at the Screening visit
  • * Elevated resting pulse greater than 100 beats per minute at Screening visit
  • * Presence of clinically significant ECG abnormalities
  • * Diagnosis of diabetes (type 1 or type 2)
  • * Participation in a weight loss program with or without pharmacotherapy during the 3 months prior to study administration
  • * Obesity induced by endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., Melanocortin 4 Receptor deficiency or Prader-Willi Syndrome).

Ages Eligible for Study

18 Years to 70 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Metsera,

Study Record Dates

2026-01-03